Donor Activating KIR3DS1 is Associated with Decreased Acute GVHD in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2010 Feb 4

PMID 20124216

Citations 51

Authors

Jeffrey M Venstrom

Ted A Gooley

Stephen Spellman

James Pring

Mari Malkki

Bo Dupont

Effie Petersdorf

Katharine C Hsu

Affiliations

Soon will be listed here.

Abstract

The natural killer cell receptor KIR3DS1 is associated with improved outcome in malignancies, infections, and autoimmune diseases, but data for the impact of KIR3DS1 in HSCT are inconsistent. Using genomic DNA from the National Marrow Donor Program, we performed donor KIR genotyping for 1087 patients who received an unrelated hematopoietic stem cell transplantation. A total of 33% of donors were KIR3DS1(+). Compared with KIR3DS1(-) donors, donor KIR3DS1 was associated with lower-grade II-IV acute graft-versus-host disease (GVHD; odds ratio = 0.71; 95% confidence interval, 0.55-0.92; P = .009), but not with relapse (hazard ratio = 0.97; 95% confidence interval, 0.73-1.29; P = .82). Furthermore, grade II-IV acute GVHD, overall mortality, and transplantation-related mortality all decreased as the number of copies of donor KIR3DS1 increased (P = .007, P = .03, and P = .02, respectively), with the lowest failure rate occurring among patients homozygous for donor KIR3DS1. Selection of donors with KIR3DS1 may decrease acute GVHD without compromising relapse-free survival, separating the graft-versus-tumor effect from unwanted GVHD.

Citing Articles

Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.

Fein J, Shouval R, Krieger E, Spellman S, Wang T, Baldauf H Blood Adv. 2023; 8(3):581-590.

PMID: 38052043 PMC: 10837477. DOI: 10.1182/bloodadvances.2023011622.

Association of iKIR-mismatch model and donor aKIRs with better outcome in haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.

Zhang Y, Ye C, Zhu H, Zhuang Y, Chen S, Weng Y Front Immunol. 2023; 13:1091188.

PMID: 36761162 PMC: 9904326. DOI: 10.3389/fimmu.2022.1091188.

Killer-Cell Immunoglobulin-like Receptor Diversity in an Admixed South American Population.

Castrillon M, Marin N, Karduss-Urueta A, Velasquez S, Alvarez C Cells. 2022; 11(18).

PMID: 36139351 PMC: 9496851. DOI: 10.3390/cells11182776.

Practical Considerations and Workflow in Utilizing KIR Genotyping in Transplantation Medicine.

Yawata M, Yawata N Methods Mol Biol. 2022; 2463:291-310.

PMID: 35344182 DOI: 10.1007/978-1-0716-2160-8_20.

Allele imputation for the killer cell immunoglobulin-like receptor KIR3DL1/S1.

Harrison G, Leaton L, Harrison E, Kichula K, Viken M, Shortt J PLoS Comput Biol. 2022; 18(2):e1009059.

PMID: 35192601 PMC: 8896733. DOI: 10.1371/journal.pcbi.1009059.

References

Martin M, Gao X, Lee J, Nelson G, Detels R, Goedert J . Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002; 31(4):429-34. DOI: 10.1038/ng934. View

Gumperz J, Litwin V, Phillips J, Lanier L, Parham P . The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995; 181(3):1133-44. PMC: 2191933. DOI: 10.1084/jem.181.3.1133. View

Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H . Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow.... Biol Blood Marrow Transplant. 2007; 14(1):75-87. DOI: 10.1016/j.bbmt.2007.09.012. View

Yu J, Heller G, Chewning J, Kim S, Yokoyama W, Hsu K . Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol. 2007; 179(9):5977-89. DOI: 10.4049/jimmunol.179.9.5977. View

Ljunggren H, Malmberg K . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007; 7(5):329-39. DOI: 10.1038/nri2073. View

Hsu K, Liu X, Selvakumar A, Mickelson E, OReilly R, Dupont B . Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol. 2002; 169(9):5118-29. DOI: 10.4049/jimmunol.169.9.5118. View

Hsu K, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon J . KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006; 12(8):828-36. DOI: 10.1016/j.bbmt.2006.04.008. View

Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C . Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. 2005; 107(3):1230-2. DOI: 10.1182/blood-2005-03-1039. View

Hsu K, Keever-Taylor C, Wilton A, Pinto C, Heller G, Arkun K . Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005; 105(12):4878-84. PMC: 1894998. DOI: 10.1182/blood-2004-12-4825. View

10.

Stewart C, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A . Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005; 102(37):13224-9. PMC: 1201584. DOI: 10.1073/pnas.0503594102. View

11.

Khakoo S, Thio C, Martin M, Brooks C, Gao X, Astemborski J . HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004; 305(5685):872-4. DOI: 10.1126/science.1097670. View

12.

Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg E . HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol. 2009; 83(13):6798-805. PMC: 2698561. DOI: 10.1128/JVI.00256-09. View

13.

Verheyden S, Schots R, Duquet W, Demanet C . A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005; 19(8):1446-51. DOI: 10.1038/sj.leu.2403839. View

14.

Cooley S, Trachtenberg E, Bergemann T, Saeteurn K, Klein J, Le C . Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2008; 113(3):726-32. PMC: 2628378. DOI: 10.1182/blood-2008-07-171926. View

15.

Zaia J, Sun J, Gallez-Hawkins G, Thao L, Oki A, Lacey S . The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15(3):315-25. PMC: 2770248. DOI: 10.1016/j.bbmt.2008.11.030. View

16.

De Santis D, Bishara A, Witt C, Nagler A, Brautbar C, Slavin S . Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens. 2005; 65(6):519-28. DOI: 10.1111/j.1399-0039.2005.00396.x. View

17.

Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F . Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol. 2002; 63(4):271-80. DOI: 10.1016/s0198-8859(02)00373-7. View

18.

Alter G, Martin M, Teigen N, Carr W, Suscovich T, Schneidewind A . Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007; 204(12):3027-36. PMC: 2118524. DOI: 10.1084/jem.20070695. View

19.

Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P . Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2003; 172(1):644-50. DOI: 10.4049/jimmunol.172.1.644. View

20.

Miller J, Cooley S, Parham P, Farag S, Verneris M, McQueen K . Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007; 109(11):5058-61. PMC: 1885526. DOI: 10.1182/blood-2007-01-065383. View